ArticleEpidemiology and psychiatric sciences2014
Using longitudinal imaging to map the 'relapse signature' of schizophrenia and other psychoses.
Article in Epidemiology and psychiatric sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Reduced mammillary body volume in individuals with a schizophrenia diagnosis: an analysis of the COBRE data set.Schizophrenia (Heidelberg, Germany) · 2023Article
- Microglia activation in postmortem brains with schizophrenia demonstrates distinct morphological changes between brain regions.Brain pathology (Zurich, Switzerland) · 2022Article
- Cognitive behavioral markers of neurodevelopmental trajectories in rodents.Translational psychiatry · 2021Article
- Predicting individual improvement in schizophrenia symptom severity at 1-year follow-up: Comparison of connectomic, structural, and clinical predictors.Human brain mapping · 2020Article
- The Challenge of Assessing Mild Neuroinflammation in Severe Mental Disorders.Frontiers in psychiatry · 2020Review
- Brain connectivity alterations in early psychosis: from clinical to neuroimaging staging.Translational psychiatry · 2019Article
- Linking persistent negative symptoms to amygdala-hippocampus structure in first-episode psychosis.Translational psychiatry · 2017Article
- Multi-center MRI prediction models: Predicting sex and illness course in first episode psychosis patients.NeuroImage · 2017Article
- A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.Neuroscience and biobehavioral reviews · 2016Review
- Microglial activation and progressive brain changes in schizophrenia.British journal of pharmacology · 2016Review
- Gender effects on brain changes in early-onset psychosis.European child & adolescent psychiatry · 2015Article
- Neurobiological changes of schizotypy: evidence from both volume-based morphometric analysis and resting-state functional connectivity.Schizophrenia bulletin · 2015Article
- When once is not enough: the case for repeated biopsychosocial assessments in psychosis.Epidemiology and psychiatric sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain imaging studies in schizophrenia have typically involved single assessment and cross-sectional designs, while longitudinal studies rarely incorporate more than two time points. While informative, these studies do not adequately capture potential trajectories of neurobiological change, particularly in the context of a changing clinical picture. We propose that the analysis of brain trajectories using multiple time points may inform our understanding of the illness and the effect of treatment. This paper makes the case for frequent serial neuroimaging across the course of schizophrenia psychoses and its application to active illness epsiodes to provide a detailed examination of psychosis relapse and remission.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.